Clinical Trials Logo

Filter by:
NCT ID: NCT05695300 Active, not recruiting - Infant Development Clinical Trials

Gut Health,Feces Characteristics and Growth of Infants Fed With a New Infant Organic Formula

Start date: February 3, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evauate the gut health, feces characteristics and growth of infants fed with a new study organic formula (investigational formula). 75 eligible infants of 30 days old will be enrolled at one center and randomized to feed the investigational formula, control formula, and breast milk for 3 months. Researchers will compare the three groups to evaluate the gut health, feces characteristics and growth of infants by the end of the study.

NCT ID: NCT05693974 Active, not recruiting - Ovarian Cancer Clinical Trials

Early Detection of Ovarian Cancer Using Plasma Cell-free DNA Fragmentomics (Retrospective Study)

Start date: October 1, 2022
Phase:
Study type: Observational

The purpose of this study is to enable non-invasive early detection of ovarian cancer in high-risk populations through the establishment of a multimodal machine learning model using plasma cell-free DNA fragmentomics. Plasma cell-free DNA from early stage ovarian cancer patients and healthy individuals will be subjected to whole-genome sequencing. Five diferent feature types, including Fragment Size Coverage (FSC), Fragment Size Distribution (FSD), EnD Motif (EDM), BreakPoint Motif (BPM), and Copy Number Variation (CNV) will be assessed to generate this model.

NCT ID: NCT05693935 Active, not recruiting - Schizophrenia Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia

SOLARIS
Start date: January 24, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of TV-44749 in adult participants with schizophrenia. A key secondary objective is to further evaluate the efficacy of TV-44749 based on additional parameters in adult participants with schizophrenia. A secondary objective is to evaluate the safety and tolerability of TV-44749 in adult participants with schizophrenia Another secondary objective of this study is to evaluate the efficacy of TV-44749 from baseline to endpoint in Period 1 in adult participants with schizophrenia. Total study duration is up to 61 weeks, and treatment duration is up to 56 weeks, with weekly visits during the first 8 weeks and then monthly in-clinic visits with weekly calls during the remainder of the treatment period.

NCT ID: NCT05691712 Active, not recruiting - Diabetes Mellitus Clinical Trials

A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

SURPASS-CN-INS
Start date: February 5, 2023
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.

NCT ID: NCT05691296 Active, not recruiting - Myopia Clinical Trials

The Monitoring and Intervention of Refractive Changes in Children and Teenagers in Tianjin

Start date: May 1, 2020
Phase: N/A
Study type: Interventional

The study aimed to collect multi-factor information on school-age children with pre-clinical myopia, and to identify the initial factors and warning signs of myopia.

NCT ID: NCT05690711 Active, not recruiting - Clinical trials for Brain Swelling, Large Hemispheric Infarction

A Trial of HRS8179 on Brain Swelling After Large Hemispheric Infarction

Start date: April 7, 2023
Phase: Phase 2
Study type: Interventional

The primary objective is to explore if HRS8179 could improve midline shift at 72 hours (or at time of decompressive craniectomy or comfort measures only, if earlier) in participants with large hemispheric infarction. The secondary objective is to explore if HRS8179 could improve acute neurologic status, functional outcomes, treatment requirements and safety.

NCT ID: NCT05690646 Active, not recruiting - Cardiac Surgery Clinical Trials

Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery

PEP
Start date: January 28, 2023
Phase: Phase 4
Study type: Interventional

Prophylactic effect of nirmatrelvir/ritonavir and ursodeoxycholic acid on reducing complications after cardiac surgery during covid-19 pandemics (the pep trial) is a multicenter, randomized controlled trial. The aim of the pep trial is to investigate whether prophylactic use of nirmatrelvir/ritonavir and ursodeoxycholic could reduce complications after cardiac surgery.

NCT ID: NCT05689567 Active, not recruiting - Myopia Clinical Trials

Focus-out Glasses on Emmetropization in Chinese Children

Start date: March 23, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to characterize the effects of peripheral focous-out glasses on emmetropization in non-myopic Chinese Children Aged 6-8 Years.This is a prospective, parallel-controlled randomized trial.

NCT ID: NCT05689138 Active, not recruiting - Pancreatic Cancer Clinical Trials

Using Digestive Microbial Information to Enhance the Early Detection of Pancreatic Cancer

Start date: September 1, 2020
Phase:
Study type: Observational

Pancreatic cancer (PCA) is a leading death-related cancer. There is an urgent need for accurate, noninvasive diagnostic options in the early detection of pancreatic cancer (PCA), since delayed diagnosis increases the risk of metastasis and recurrence. In this study, by analyzing gut and fecal microbial data among the pancreatic versus healthy populations, we aim to establish an early detection tool to improve PCA detection, and to explore potential diagnostic biomarkers.

NCT ID: NCT05688033 Active, not recruiting - Rectal Cancer Clinical Trials

Dosimetric Limitation of Pelvic Bone and Peritoneal Space in Rectal Cancer Patients During Chemoradiotherapy

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

This project first retrospectively analyzes the intestinal dose indicators related to the concurrent radiotherapy and chemotherapy of rectal cancer and gastrointestinal toxicity, and the pelvic dose indicators related to hematological toxicity, and then prospectively conducts radiotherapy based on the dose indicators most closely related to toxicity. The dose is limited when the plan is made to reduce the gastrointestinal and hematological toxicity of rectal cancer with concurrent radiotherapy and chemotherapy.